Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies
Kristoffer A. A. Andersen, Robin Carhart‐Harris, David Nutt, et al.
Acta Psychiatrica Scandinavica (2020) Vol. 143, Iss. 2, pp. 101-118
Closed Access | Times Cited: 253

Showing 1-25 of 253 citing articles:

Novel and emerging treatments for major depression
Steven Marwaha, Edward Palmer, Trisha Suppes, et al.
The Lancet (2022) Vol. 401, Iss. 10371, pp. 141-153
Open Access | Times Cited: 304
Increased global integration in the brain after psilocybin therapy for depression
Richard E. Daws, Christopher Timmermann, Bruna Giribaldi, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 844-851
Open Access | Times Cited: 303
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Rafael Moliner, Mykhailo Girych, Cecilia A. Brunello, et al.
Nature Neuroscience (2023) Vol. 26, Iss. 6, pp. 1032-1041
Open Access | Times Cited: 225
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Anne Katrin Schlag, Jacob S. Aday, Iram Salam, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 3, pp. 258-272
Open Access | Times Cited: 220
Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Cato M. H. de Vos, Natasha L. Mason, Kim P. C. Kuypers
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 168
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Lily R. Aleksandrova, Anthony G. Phillips
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 11, pp. 929-942
Closed Access | Times Cited: 161
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
Kwonmok Ko, Gemma Knight, James Rucker, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 153
Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression
Roberta Murphy, Hannes Kettner, Rick Zeifman, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 140
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Joost J. Breeksema, Bouwe Kuin, Jeanine Kamphuis, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 10, pp. 1100-1117
Open Access | Times Cited: 126
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
Michiel van Elk, David B. Yaden
Neuroscience & Biobehavioral Reviews (2022) Vol. 140, pp. 104793-104793
Open Access | Times Cited: 106
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience
Joseph Peill, Katie Trinci, Hannes Kettner, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 1, pp. 31-45
Open Access | Times Cited: 102
The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
Christoph U. Correll, Marco Solmi, Samuele Cortese, et al.
World Psychiatry (2023) Vol. 22, Iss. 1, pp. 48-74
Open Access | Times Cited: 81
Therapeutic effect of psilocybin in addiction: A systematic review
Pim B. van der Meer, Juan José Fuentes, Ad A. Kaptein, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 72
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 15
Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism
Katherine Cheung, Brian D. Earp, Kyle Patch, et al.
The American Journal of Bioethics (2025) Vol. 25, Iss. 1, pp. 16-28
Closed Access | Times Cited: 14
The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials
Lavinia Hogea, Dana Cătălina Tabugan, Iuliana Costea, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 278-278
Open Access | Times Cited: 2
Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes
Gabrielle Agin-Liebes, Trevor Forrest Haas, Rafael Lancelotta, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 543-552
Open Access | Times Cited: 95
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Mauro Cavarra, Alessandra Falzone, Johannes G. Ramaekers, et al.
Frontiers in Psychology (2022) Vol. 13
Open Access | Times Cited: 67
Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research
David A. Bender, David J. Hellerstein
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1907-1932
Closed Access | Times Cited: 64
Psychedelics therapeutics: What we know, what we think, and what we need to research
David Nutt, Meg J. Spriggs, David Erritzøe
Neuropharmacology (2022) Vol. 223, pp. 109257-109257
Open Access | Times Cited: 64
Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
Meg J. Spriggs, Hannah Douglass, Rebecca J. Park, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 59
Expectancy in placebo-controlled trials of psychedelics: if so, so what?
Matthew Butler, Luke A. Jelen, James Rucker
Psychopharmacology (2022) Vol. 239, Iss. 10, pp. 3047-3055
Open Access | Times Cited: 54
Acute psilocybin enhances cognitive flexibility in rats
Alejandro Torrado Pacheco, Randall J. Olson, Gabriela Garza, et al.
Neuropsychopharmacology (2023) Vol. 48, Iss. 7, pp. 1011-1020
Open Access | Times Cited: 39
Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT
Steven A. Barker
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1749-1763
Open Access | Times Cited: 38
Psychedelic therapy in the treatment of addiction: the past, present and future
Rayyan Zafar, Maxim Siegel, Rebecca Harding, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top